Suppr超能文献

局部进展期结肠癌患者基于围手术期化疗和手术的治疗策略的初步结果。

Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer.

机构信息

Department of General Surgery, Clínica Universidad de Navarra, Navarra, Spain.

出版信息

Colorectal Dis. 2013 May;15(5):552-7. doi: 10.1111/codi.12119.

Abstract

AIM

Preoperative chemotherapy followed by radical surgery is an attractive treatment for locally advanced colon cancer (LACC) given the promising results of this approach in other locally advanced tumours. The study evaluates the outcome and treatment-related complications of perioperative oxaliplatin- and capecitabine-based chemotherapy and surgery for clinical Stage III colon cancer.

METHOD

Twenty-two consecutive patients with a CT-staged LACC were included. All were staged at baseline and before surgery. Surgery-related complications and oncological outcome were determined.

RESULTS

Toxicity was manageable, with 19/22 patients completing the planned chemotherapy protocol. The median time from initial diagnosis to surgery was 65.5 days. The median time from the end of chemotherapy to surgery was 22 days. After neoadjuvant treatment, tumour reduction of 69.5% was observed by CT scan and a 59.9% decrease of SUVmax (standard uptake value) was achieved on positron emission tomography/CT. No progressive disease was reported during preoperative chemotherapy and surgery was performed in all 22 patients. Four patients developed postoperative complications. After a median postoperative follow-up of 14.4 months, the actuarial overall and disease-free survival rates were 100 and 90%.

CONCLUSION

Neoadjuvant chemotherapy followed by surgery and chemotherapy for LACC is safe without apparent increase of early and medium-term complications.

摘要

目的

术前化疗加根治性手术是治疗局部晚期结肠癌(LACC)的一种有吸引力的方法,因为这种方法在其他局部晚期肿瘤中的疗效令人鼓舞。本研究评估了奥沙利铂和卡培他滨为基础的围手术期化疗和手术治疗临床 III 期结肠癌的结果和与治疗相关的并发症。

方法

连续纳入 22 例 CT 分期为 LACC 的患者。所有患者均在基线和术前进行分期。确定手术相关并发症和肿瘤学结果。

结果

毒性可控制,22 例患者中有 19 例完成了计划的化疗方案。从初始诊断到手术的中位时间为 65.5 天。从化疗结束到手术的中位时间为 22 天。新辅助治疗后,CT 扫描观察到肿瘤缩小 69.5%,正电子发射断层扫描/CT 上的 SUVmax(标准摄取值)下降 59.9%。在术前化疗期间未报告进行性疾病,所有 22 例患者均进行了手术。4 例患者术后出现并发症。在中位术后随访 14.4 个月后,总生存率和无病生存率的累积率分别为 100%和 90%。

结论

LACC 患者行新辅助化疗后手术及化疗是安全的,并未明显增加早期和中期并发症。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验